肝细胞癌经动脉化疗栓塞术后第一天的CT灌注早期反应评估可预测治疗反应和长期疾病控制
本研究纳入16例患者的41个肝细胞癌病灶,在经动脉化疗栓塞术(TACE)前及术后第一天行CT灌注(CTP)检查,测量血流灌注参数并与术后六周mRECIST评估的反应及长期结局比较。结果显示反应者TACE后CTP参数显著降低,ALPpost预测完全缓解的敏感度、特异度、阳性预测值、阴性预测值和准确率分别为90%、90%、91%、90%和91%。结论认为CT灌注可在TACE后一天检测出完全缓解病灶,是早期反应评估的可行工具。
要点
- TACE后第一天CT灌注参数在反应者中显著降低,非反应者无差异。
- ALPpost预测完全缓解的敏感度90%、特异度90%、准确率91%。
- 21个完全缓解病灶中仅3个复发,平均局部无复发生存期19.6个月。
核心结论
- CT灌注可在TACE后一天检测出完全缓解病灶,是早期反应评估的可行工具。
研究设计与样本
- 2013年4月至2015年4月纳入16例患者的41个肝细胞癌病灶,TACE前及术后一天行CT灌注检查,测量BF、BV、TTS、ALP、PVP和HPI,并与术后六周mRECIST评估的反应及长期结局比较。
关键影像表现/征象
- 反应者(部分缓解、完全缓解)TACE后CT灌注参数显著降低(p<0.001),非反应者无差异。
- TACE后六周21个病灶(51%)达完全缓解,5个(12%)达部分缓解。
- 21个完全缓解病灶中仅3个复发,平均局部无复发生存期19.6个月。
诊断标准与关键数值
- ALPpost预测完全缓解优于BFpost和BVpost(p<0.001),敏感度90%、特异度90%、阳性预测值91%、阴性预测值90%、准确率91%。
临床应用与阅片要点
- TACE后第一天CT灌注参数降低可早期提示治疗反应,ALPpost对完全缓解的预测价值较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the value of CT perfusion (CTP) for early response assessment after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Between April 2013 and April 2015, 41 HCC (16 patients) were included in this study. CT perfusion was performed before and one day after TACE. Blood flow (BF), blood volume (BV), time to start (TTS), arterial liver perfusion (ALP), portal liver perfusion (PVP) and hepatic perfusion index (HPI) were measured. Quantitative perfusion values before and after TACE were compared to the response assessed using mRECIST criteria six weeks after TACE and long-term outcome was assessed.
RESULTS: Twenty-one lesions (51%) had complete remission (CR) and five (12%) had partial response (PR) six weeks after TACE. CTP parameters were significantly reduced after TACE in responders (PR, CR, p<0.001) while no difference was observed in non-responders. ALPpost was superior in the prediction of CR compared to BFpost and BVpost (p<0.001) with a sensitivity, specificity, PPV, NPV, and accuracy of 90%, 90%, 91%, 90%, and 91%, respectively. Only 3/21 lesions with CR recurred, with a mean local-recurrence-free survival of 19.6 months.
CONCLUSION: CT perfusion detects lesions with complete response one day after TACE, and is a feasible tool for early response assessment.
引用
- Tamandl D, Waneck F, Sieghart W, et al. Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. Eur J Radiol. 2017. PMID: 28583650. doi:10.1016/j.ejrad.2017.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。